BioCentury
ARTICLE | Clinical News

May 22 Clinical Quick Takes: Lilly's mirikizumab meets Crohn's endpoints; plus Novartis, 89bio and more

May 22, 2019 10:44 PM UTC

Lilly's mirikizumab meets in Phase II for Crohn’s
Mirikizumab (LY3074828) from Eli Lilly and Co. (NYSE:LLY) met the primary and secondary endpoints of improving clinical and endoscopic measures of disease activity at week 12 vs. placebo in the Phase II SERENITY trial to treat moderately to severely active Crohn’s disease. The pharma plans to start this year a Phase III trial of the humanized IgG4 mAb that binds the IL-23 subunit α (IL23P19; IL-23A) for the indication.

Phase II meet for Novartis asthma triplet
Also reporting positive Phase II data on Wednesday was Novartis AG (NYSE:NVS; SIX:NOVN), which said both doses of its once-daily asthma therapy comprising indacaterol, glycopyrronium bromide and mometasone fuorate (QVM149) delivered with the Breezhaler inhalation device met the primary endpoint of improving peak forced expiratory volume in 1 second (FEV1) vs. twice-daily Advair salmeterol/fluticasone from GlaxoSmithKline plc (NYSE:GSK; LSE:GSK) (mean differences of 159 and 172 mL, respectively, p<0.001). In a separate Phase II trial in asthma patients, QVM149 was superior to placebo in improving lung function regardless of administration time of morning or evening. QVM149 is in Phase III testing for the indication...